Irreversible EGFR Inhibitors in the Treatment of Advanced NSCLC

Author(s): Paolo Maione, Antonio Rossi, Marianna Bareschino, Paola Claudia Sacco, Clorinda Schettino, Francesca Casaluce, Assunta Sgambato, Cesare Gridelli

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 24 , 2014

Become EABM
Become Reviewer
Call for Editor


The epidermal growth factor receptor (EGFR) is among the most important targets in the treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small molecules, are reversible EGFR tyrosine kinase inhibitors (TKIs). Non-small cell lung cancers with EGFR mutations, are characterized by excellent responses when treated with the EGFR-TKIs gefitinib and erlotinib. However, all the patients with tumors harbouring EGFR mutations experience disease progression after a median of 10 to 14 months of treatment with gefitinib or erlotinib. A group of new generation EGFR-TKIs irreversibly inhibit EGFR-TK and represent one of the strategies that may potentially overcome the acquired resistance to gefitinib and erlotinib or achieve better outcomes than reversible inhibitors in the first-line treatment of EGFR mutant lung cancers. Afatinib (BIBW 2992) and PF299804 are the irreversible EGFR-TKIs with the most relevant data in the treatment of advanced NSCLC, as primary EGFR-targeted therapy and after resistance to reversible EGFR-TKIs. However, to date, the role of irreversible EGFR inhibitors remains to be defined.

Keywords: Advanced NSCLC, EGFR, irreversible inhibitors, afatinib, PF299804.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 05 November, 2013
Page: [3894 - 3900]
Pages: 7
DOI: 10.2174/13816128113196660764
Price: $65

Article Metrics

PDF: 62